Clinical Trials Directory

Trials / Completed

CompletedNCT00393003

Target-controlled Infusion of Propofol and Remifentanil for Postoperative Sedation Guided by the Bispectral Index

Target-controlled Infusion of Propofol and Remifentanil for Postoperative Sedation Guided by the Bispectral Index: Comparison Between Manual Perfusion and Automated Perfusion

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
32 (planned)
Sponsor
Hopital Foch · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This prospective randomized study evaluates the effectiveness of a closed-loop anesthesia system during the postoperative period.

Detailed description

The Bispectral Index (BIS) is an electroencephalogram-derived measure of anesthetic depth. A closed-loop anesthesia system can be built using BIS as the control variable, two proportional-integral-differential control algorithms, a propofol and a remifentanil target-controlled infusion systems as the control actuators. Preliminary results show that this system can be used during surgery. We propose a prospective randomized study to evaluate the effectiveness of such a closed-loop anesthesia system during the postoperative period. Two groups of patients are compared: one in which propofol and remifentanil are administered by the anesthesiologist using target-controlled infusion systems, and one in which propofol and remifentanil are administered automatically by the combined closed-loop anesthesia system. In both groups, the goal is to maintain BIS between 40 and 60, the recommended range during anesthesia by the manufacturer. We expect the combined closed-loop system group to do similar or better.

Conditions

Interventions

TypeNameDescription
DEVICEClosed-loop anesthesia system

Timeline

Start date
2006-09-01
Primary completion
2007-04-01
Completion
2007-04-01
First posted
2006-10-26
Last updated
2009-08-31

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT00393003. Inclusion in this directory is not an endorsement.